It is true that the benefit of cetuximab or panitumumab, two well-known EGFR mAb approved by FDA, is restricted to patients with KRAS wild-type colorectal cancer, and only this subset of patients should receive these agents [54]. Here, EGFR is linked to colorectal cancer.